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Clinical research has been a key part of the government’s response to the coronavirus pandemic and its plan to con-
tain, delay, research and mitigate (Scally et 
al, 2020). To date, Covid-19 research has 
mainly focused on clinical trials to: 
l	 	Identify and plot the course of the 
disease to better understand it; 
l	 	Identify and test existing drugs that 
may help treat symptoms or reduce the 
impact of the virus; 
l	 	Test a vaccine. 
Clinical research nurses and midwives 
have been central to the rapid implementa-
tion of these clinical trials (Jones et al, 
2020). Nurses and midwives working on 
wards and in clinical departments during 
the pandemic may also have supported or 
seen research staff collecting patients’ 
consent and data; these are the most visible 
elements of delivering clinical trials. There 
is less knowledge and awareness of the 
huge ‘behind-the-scenes’ effort and organi-
sation required to enable patients across 
the UK to contribute, through research, to 
understanding and treating the virus. 
This article illustrates how research 
delivery, along with the work of clinical 
research nurses and midwives, has been 
crucial in underpinning the research effort 
during the coronavirus pandemic. In par-
ticular, it focuses on the challenges of, and 
adaptations to, informed consent, data col-
lection and drug delivery in the high-risk 
context of Covid-19 care in hospitals, and 
includes specific examples. It also high-
lights the varied practices and innovations 
applied by research nurses and midwives 
across organisations.
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In this article...
l   The research taking place into possible treatments for Covid-19
l   How the pandemic has affected standard research delivery practices
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ultimately, enabled treatment options to 
be offered to patients for a disease that has 
no known cure. At the start of the pan-
demic, most existing research studies were 
suspended; only those essential to patient 
safety continued, supported by a skeleton 
research workforce. Some research teams 
were redeployed clinically to support areas 
such as intensive care, while others quickly 
adapted to infectious disease research. 
Standard research procedures include 
identifying potential participants, sup-
porting the informed-consent process, col-
lecting biological samples, collecting clin-
ical and demographic data, and delivering 
novel trial drugs. Supporting participants 
and their families during the clinical and 
trial procedures is also a key part of a 
research nurse or midwife’s role. For 
Covid-19 trials, it has been necessary to 
design, in which a single master protocol 
enables multiple drugs to be evaluated 
simultaneously. This design means a study 
can adapt to include or discontinue treat-
ment arms as new information emerges, to 
ensure the most up-to-date treatment 
options are available (Saville and Berry, 
2016). As such, research nurses and mid-
wives have needed to learn quickly about 
such trials and the drug treatments used. 
Box 1 illustrates some of the CMO-
endorsed studies that research nurses and 
midwives have been supporting.
Challenges for research  
nurses and midwives
Clinical research nurses and midwives 
have been pivotal in the early set-up 
and implementation of CMO-endorsed 
Covid-19 research trials; this has, 
Covid-19 research studies
Developing drugs to treat new diseases is 
often a long, involved process that takes 
10-15 years. In response to the emergence 
of SARS-Cov-2, the novel coronavirus 
responsible for the current pandemic, 
research became key. To identify potential 
treatments in a timely manner, 
researchers and pharmaceutical compa-
nies focused on drugs that had already 
been tested and licensed to treat inflam-
matory diseases (such as rheumatoid 
arthritis) or viral pathogens (such as Ebola 
and HIV) in the hope that they would 
effectively treat Covid-19, the disease 
caused by SARS-Cov-2. 
Tocilizumab is one such drug: this bio-
logical anti-inflammatory therapy 
licensed for the treatment of rheumatoid 
arthritis is being trialled to investigate 
whether it ameliorates the cytokine cas-
cade (whole-body acute inflammatory 
response) seen in severe cases of Covid-19 
and, thus, improves outcomes. 
One drug already shown to be beneficial 
is remdesivir, a broad-spectrum anti-viral 
medication developed to treat Ebola. Pro-
gress has been swift and early results show 
it reduces hospitalised patients’ recovery 
time by 30%; the drug is now available for 
the treatment of adults and children with 
severe Covid-19 (Beigel et al, 2020). 
Data from the RECOVERY trial (Box 1) 
has reported that treating patients on res-
piratory support with dexamethasone 
reduces mortality by 36% for those who are 
ventilated and 18% for those on oxygen 
(RECOVERY Collaborative Group, 2020). 
These are just a few examples from the 
vast amount of ongoing research; by mid-
May 2020, more than 1,000 Covid-19 clin-
ical trials involving >150 treatments were 
running globally (Bit.ly/ABPIPharmCovid).
Clinical research is a routine aspect of 
most acute trusts’ workload. Research 
teams can be found across many key areas, 
such as oncology, haematology, cardiovas-
cular disease and musculoskeletal disease. 
Most acute trusts develop a bespoke port-
folio of recruiting studies based on their 
clinical specialties and some develop their 
own specialist research teams in rare dis-
ease areas. At the onset of the coronavirus 
pandemic, however, a more centralised 
system of research trials was developed. 
To maximise patient recruitment and 
swiftly identify beneficial therapeutic 
options that could be developed into treat-
ment pathways, trusts were encouraged to 
prioritise studies approved by the UK’s 
four chief medical officers (CMOs). Many 
of these studies use an adaptive platform 
Clinical Practice
Discussion
Box 1. UK prioritised, CMO-endorsed Covid-19 research trials
RECOVERY trial 
This is a randomised trial of adults, maternity patients and children hospitalised for 
confirmed Covid-19. Eligible participants are randomly allocated to one of several 
treatment arms, each of which offers an intervention given in addition to the usual 
standard of care. The main aim of the study is to review the effect of each treatment on 
in-hospital death, discharge and need for ventilation. Current treatment arms include:
l		Lopinavir-ritonavir (commonly used to treat HIV) – initial treatment arm; now 
discontinued as no benefit found
l		Low-dose dexamethasone (a steroid used for a range of conditions, typically to 
reduce inflammation) – now only recruiting children, already licensed for use in adults
l		Azithromycin (a commonly used antibiotic)
l		Tocilizumab (an anti-inflammatory treatment given by injection)
l		Convalescent plasma (collected from donors who have recovered from Covid-19; 
contains antibodies against the SARS-Cov-2 virus)
Read more at Bit.ly/RECOVERYtrial 
REMAP-CAP trial
This trial aims to determine the best range of treatments for patients who become 
severely ill and are admitted to intensive care units due to Covid-19. It is evaluating:
l		Different antiviral drugs 
l		Steroids to reduce inflammation
l		Treatments that act on the immune system and are often used to treat other 
conditions, such as rheumatoid arthritis (interferon-ß1a, anakinra, tocilizumab  
and sarilumab)
The trial will investigate how these drugs work in combination, with additional 
treatments added over time. 
Read more at Bit.ly/REMAP-CAPtrial
RECOVERY-RS trial 
This is a respiratory support trial. People who have been intubated and ventilated are 
excluded. Eligible patients are randomised to receive one of three treatment options: 
l		High-flow nasal oxygen (HFNO)
l		Continuous positive airway pressure (CPAP)
l		Standard care for patients diagnosed with Covid-19
The study aims to determine whether HFNO or CPAP is clinically effective 
compared with standard care. 
Read more at Bit.ly/RECOVERY-RStrial
CMO = chief medical officer
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hoods were not always available; this neces-
sitated support from external laboratories 
and volunteer laboratory staff with the 
required specialist skills. 
Drug delivery 
The administration of clinical trial drugs 
also poses challenges. Dispensing and 
administering trial drugs follows standard 
procedures, but patients are randomised 
to receive either the active drug or a pla-
cebo. This, along with the fact that the 
labelling and handling of clinical trial 
drugs is often different to (and more com-
plicated) that of regular medicines, has 
put extra pressure on pharmacy depart-
ments that are already stretched. 
When drugs are on a ward, IPC meas-
ures and documenting trial drugs also add 
to the complexity of administration. 
Conclusion
The pandemic has taught us that we need 
to be ‘research ready’ for public health 
emergencies and that emergency plans 
need to include careful consideration of 
the research workforce. Flexibility and 
contingency planning must be built into 
research protocols so they are practical 
and feasible to implement in a pandemic. 
Solutions must be found to enable all 
patients affected by infectious diseases to 
participate in research if they so wish. 
Clinical research nurses, midwives and 
practitioners have enabled >130,000 UK 
patients to participate in Covid-19 research, 
classified as “urgent public-health 
research”, over a very short period of time 
(National Institute for Health Research, 
2020). Their adaptability, skill and commit-
ment to finding viable treatments and vac-
cines highlight the need to recognise, train 
and retain this crucial group. NT
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tions to navigate this issue, including: 
l	 	Photographing the consent form 
through a bay or side room internal 
window, then uploading the photo 
using the secure application Pando;
l	 	Taking consent from a witness who can 
sign the consent form away from the 
Covid-19-positive area so the usual 
governance processes can be followed. 
Data collection
Additional hurdles exist around data collec-
tion, as this usually involves use of paper-
based documents to record procedures and 
clinical and demographic data. Restrictions 
on removing paperwork from a Covid-
19-positive environment have meant 
research data must be added to a patient’s 
electronic care record via a PC or tablet; data 
extraction and entry into specific trial data-
bases is then required at a later date. 
As there have been so many patients 
with Covid-19 in ward areas, much data 
has been collected by research nurses and 
practitioners. Research nurses shielding at 
home also made a significant contribution 
by supporting this remotely. A huge ben-
efit has been the ability to upload data in 
real time – as an example, live information 
from the national database for the Interna-
tional Severe Acute Respiratory and 
Emerging Infection Consortium’s corona-
virus clinical characterisation consortium 
was shared with the government to help 
guide decisions and policies around the 
UK’s response to the pandemic.
Sample collection
The collection and processing of blood and 
other biological samples have also been 
complicated by IPC measures. To reduce the 
number of staff exposed to Covid-19 and 
conserve personal protective equipment, 
research staff collaborated closely with clin-
ical nurses and phlebotomists, combining 
the collection of routine and research sam-
ples to reduce both teams’ workloads. 
Samples placed into a high-risk biolog-
ical sample bag in a Covid-19 area are trans-
ferred at the door of the isolation bay or 
room into a clean sample bag, which is held 
by a nurse or researcher on the ‘clean’ side 
of the door. As the samples  are infected, 
laboratory processing requires a specialist 
class 2 hood for air extraction. When 
sample processing was at its busiest, class 2 
adapt and innovate so these procedures can 
be delivered within a context of severely ill 
patients, absent family and the required 
isolation and infection control procedures. 
Informed consent
Gaining informed consent has been a 
notable challenge. In normal circum-
stances, potential trial participants receive 
verbal and written information and time to 
consider the particular study, with discus-
sions often involving their family or GP. 
They must show they fully comprehend the 
study and its personal impact and have the 
capacity to give their consent (Biros, 2018). 
However, many patients admitted to hos-
pital with Covid-19 are too unwell to fully 
engage with the standard practices of 
taking informed consent and demon-
strating capacity. In these situations: 
l	 	Clinical research doctors and nurses try 
to explain the study to potential 
participants and receive verbal consent; 
l	 	An independent doctor or nurse from 
the clinical team is present to verify that 
the study is in the patient’s best 
interests, the patient receives an 
explanation of what is involved and 
verbally agrees to participate;
l	 	A witness consent form is signed by the 
independent clinician, not the patient. 
Obtaining consent from patients who 
are so unwell they have lost capacity has 
presented different challenges. Ordinarily, 
in this situation, the next of kin is con-
sulted and asked to give consent on the 
patient’s behalf; however, during the pan-
demic, relatives have been unable to visit 
patients, so this has not been possible. 
Instead, a clinician responsible for the 
patient’s care, but independent of the trial, 
acts as a legal representative and gives con-
sent on the patient’s behalf, confirming 
participation is in their best interest. 
Whenever possible, this has been preceded 
by a telephone discussion with the patient’s 
relatives to ensure they are informed. 
The logistics of complying with infec-
tion prevention and control (IPC) meas-
ures has also posed challenges. It is a regu-
latory requirement to take three copies of 
the signed consent form: one is for the 
patient, one remains in patient’s notes, 
and the other is filed in the research study 
folder. In line with IPC guidance, items 
from the room or bed area of a patient who 
is Covid-19 positive must be quarantined 
for 5-14 days (depending on local policy) 
before they can be fully accessed. Usual 
practices have, therefore, needed to be 
reviewed to ensure compliance.
Teams have developed various solu-
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